Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

J&J, CSIR-IMTECH Reveal New Development Partnership for TB Treatments

By Johnson & Johnson | August 28, 2017

Johnson & Johnson Private Limited announced a new partnership with the Institute of Microbial Technology (IMTECH), part of the Council of Scientific and Industrial Research (CSIR), to unlock the potential of Indian science and help accelerate the discovery of innovative new treatments for tuberculosis (TB).

Under the Memorandum of Understanding, scientists from Johnson & Johnson’s global public health team will work closely with scientists from CSIR-IMTECH, based in Chandigarh, India, on a research and development program to explore potentially more effective, safer, all-oral treatment regimens to tackle multidrug-resistant TB (MDR-TB), as well as new molecular entities to treat all TB patients.

“We are united with India in our determination to make TB history,” said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson, who joined Dr Harsh Vardhan, Minister for Science and Technology, at an event in New Delhi, to announce the Memorandum of Understanding. “While we have made great advances in recent years with the approval of new TB medicines much more needs to be done. By bringing together some of India’s brightest minds with our scientists, we increase the potential to achieve major research breakthroughs that can lead toinnovative new treatments for the millions of people in India and around the world who suffer from TB.”

The new research program will capitalize on CSIR-IMTECH’s world-class expertise in microbial technology and research and the proven research and development capabilities of Johnson & Johnson’s Janssen Pharmaceutical Companies to strengthen the collective potential of our research efforts.

“TB remains a significant challenge in India, killing approximately half a million-people in 2015 alone,” said Dr. Anil Koul, Director, CSIR-IMTECH. “The partnership we have announced today with Johnson & Johnson has the potential to accelerate our work in support of India’s National Strategic Plan, our accelerated action plan to End TB by 2025, and most importantly save lives.”

Today’s announcement builds on nearly 20 years of TB research and development by Johnson & Johnson,which led to the approval of bedaquiline, the first new TB medicine in nearly 50 years, and adds to existing partnerships at central and state levels in India to increase awareness, diagnosis and care, and broaden access to bedaquiline.

In March 2016, Janssen India and the Revised National Tuberculosis Control Program (under the aegis of the Director General of Health Services) announced a Conditional Access Program (CAP) to provide bedaquiline free-of-charge for 600 patients across six sites in India.

In April 2017, it was confirmed that the CAP would be expanded to additional TB patients across 156 sites.Janssen India has also partnered with authorities in Mumbai, Telangana, Patna and Nagpur to increase awareness of TB and improve access to diagnosis, treatment and care.

“Johnson & Johnson companies have been serving the healthcare needs of India for seventy years now; and this partnership forms an important part of our commitment to the government’s ‘Make in India’ program, supporting Indian drug development for a disease that affects more than 2.8 million people in our country,” added Sanjiv Navangul, Managing Director, Janssen India.

Related Articles Read More >

Eli Lilly facility
9 R&D developments this week: Lilly builds major R&D center, Stratolaunch tests hypersonic craft, IBM chief urges AI R&D funding
professional photo of wooly mammoth in nature --ar 2:1 --personalize sq85hce --v 6.1 Job ID: 47185eaa-b213-4624-8bee-44f9e882feaa
Why science ethicists are sounding skepticism and alarm on ‘de-extinction’
ALAFIA system speeds complex molecular simulations for University of Miami drug research
3d rendered illustration of the anatomy of a cancer cell
Funding flows to obesity, oncology and immunology: 2024 sales data show where science is paying off
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE